Hostname: page-component-6766d58669-tq7bh Total loading time: 0 Render date: 2026-05-19T09:37:35.739Z Has data issue: false hasContentIssue false
  • English
  • Français

Biological therapy of salivary duct carcinoma

Published online by Cambridge University Press:  11 April 2008

M Nashed  and
R J Casasola
M Nashed*
Affiliation:
Oncology Department, Ninewells Hospital & Medical School, Dundee, Scotland, UK
R J Casasola
Affiliation:
Oncology Department, Ninewells Hospital & Medical School, Dundee, Scotland, UK
*
Address for correspondence: Dr M Nashed, Oncology Department, Ninewells Hospital & Medical School, Dundee DD1 9SY, Scotland, UK. E-mail: m.nashed@nhs.net
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

The incidence of human epidermal growth factor receptor 2 positivity in salivary duct carcinoma ranges from 25 to 100 per cent and is associated with a poor outcome. Salivary duct carcinoma has significant pathological similarities to ductal carcinoma of the breast.

Methods and results:

A 49-year-old man developed lung and liver metastasis a few months after surgery and adjuvant radiotherapy for salivary duct carcinoma of the parotid gland. There was no response to palliative chemotherapy with doxorubicin. We followed the biological model of breast cancer, whereby two-thirds of human epidermal growth factor receptor 2 positive patients respond to a combination of docetaxel and human epidermal growth factor receptor 2 blocker (trastuzumab). A durable, complete response was achieved with this combination. A rationalised treatment approach targeting the biological characteristics of salivary duct carcinoma had proven successful.

Keywords

Salivary DuctCarcinomaTrastuzumabDocetaxelHer-2

Information

Type
Clinical Records
Information
The Journal of Laryngology & Otology , Volume 123 , Issue 2 , February 2009 , pp. 250 - 252
Copyright
Copyright © JLO (1984) Limited 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1Jaehne, M, Roeser, K, Jaekel, T, Schepers, JD, Albert, N, Loning, T. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 2005;103:2526–33CrossRefGoogle ScholarPubMed
2De Potter, CR. The neu-oncogene: more than a prognostic indicator? Hum Pathol 1994;25:1264–8CrossRefGoogle ScholarPubMed
3Pegram, MD, Lipton, A, Hayes, DF, Weber, BL, Baselga, JM, Tripathy, D et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659–71CrossRefGoogle ScholarPubMed
4Skalova, A, Starek, I, Vanecek, T, Kucerova, V, Plank, L, Szepe, P et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 2003;42:348–56CrossRefGoogle ScholarPubMed
5Dagrada, GP, Negri, T, Tamborini, E, Pierotti, MA, Pilotti, S. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 2004;44:301–2CrossRefGoogle ScholarPubMed
6Hellquist, HB, Karlsson, MG, Nilsson, C. Salivary duct carcinoma – a highly aggressive salivary gland tumour with overexpression of c-erbB-2. J Pathol 1994;172:35–44CrossRefGoogle ScholarPubMed
7Etges, A, Pinto, DS Jr, Kowalski, LP, Soares, FA, Araujo, VC. Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. J Clin Pathol 2003;56:914–18CrossRefGoogle ScholarPubMed
8Skalova, A, Starek, I, Kucerova, V, Szepe, P, Plank, L. Salivary duct carcinoma – a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. Pathol Res Pract 2001;197:621–6CrossRefGoogle ScholarPubMed
9Barnes, L, Rao, U, Contis, L, Krause, J, Schwartz, A, Scalamogna, P. Salivary duct carcinoma. Part II. Immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D, and c-erbB-2 protein. Oral Surg Oral Med Oral Pathol 1994;78:74–80CrossRefGoogle ScholarPubMed
10Felix, A, El-Naggar, AK, Press, MF, Ordonez, NG, Fonseca, I, Tucker, SL et al. Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol 1996;27:561–6CrossRefGoogle ScholarPubMed
11Marty, M, Cognetti, F, Maraninchi, D, Snyder, R, Mauriac, L, Tubiana-Hulin, M et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265–74CrossRefGoogle ScholarPubMed
12Pegram, MD, Konecny, GE, O'Callaghan, C, Beryt, M, Pietras, R, Slamon, DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739–49CrossRefGoogle ScholarPubMed
13Sato, N, Sano, M, Tabei, T, Asaga, T, Ando, J, Fujii, H et al. Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study. Breast Cancer 2006;13:166–71CrossRefGoogle ScholarPubMed